HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?

EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection

(2015)   JOURNAL OF HEPATOLOGY

Tenofovir-associated Fanconi Syndrome in patients with chronic hepatitis B monoinfection

(2013) David M Gracey et al.   ANTIVIRAL THERAPY

Results of Treatment of Chronic Hepatitis B with Pegylated Interferon

(2013) Mauro Viganò et al.   Clinics in Liver Disease

Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients

(2013) Wen-Juei Jeng et al.   HEPATOLOGY

Long-term therapy for chronic hepatitis B: Hepatitis B virus DNA suppression leading to cirrhosis reversal

(2013) Patrick Marcellin et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

43 LONG TERM TENOFOVIR DISOPROXIL FUMARATE (TDF) THERAPY AND THE RISK OF HEPATOCELLULAR CARCINOMA

(2013) W.R. Kim et al.   JOURNAL OF HEPATOLOGY

768 EFFECTIVENESS OF TENOFOVIR FOR CHRONIC HEPATITIS B IN FIELD PRACTICE – 2 YEAR INTERIM RESULTS FROM THE PROSPECTIVE GERMAN MULTICENTER NON-INTERVENTIONAL STUDY (GEMINIS)

(2013) J. Petersen et al.   JOURNAL OF HEPATOLOGY

744 TENOFOVIR DF (TDF) IS SAFE AND WELL TOLERATED IN CHRONIC HEPATITIS B (CHB) PATIENTS WITH PRE-EXISTING MILD RENAL IMPAIRMENT

(2013) S. Fung et al.   JOURNAL OF HEPATOLOGY

748 VIROLOGICAL RESPONSE AND TOLERANCE OF TENOFOVIR DF (TDF) IN THE ELDERLY IS SIMILAR TO YOUNGER PATIENTS IN REAL LIFE PRACTICE

(2013) C. Hézode et al.   JOURNAL OF HEPATOLOGY

755 5-YEAR ENTECAVIR TREATMENT IN NUC-NAÏVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS

(2013) P. Lampertico et al.   JOURNAL OF HEPATOLOGY

44 PERFORMANCE OF HEPATOCELLULAR CARCINOMA RISK SCORES IN CHRONIC HEPATITIS B PATIENTS RECEIVING ENTECAVIR TREATMENT

(2013) V.W.-S. Wong et al.   JOURNAL OF HEPATOLOGY

The role of HBsAg quantification for monitoring natural history and treatment outcome

(2013) Michelle Martinot-Peignoux et al.   LIVER INTERNATIONAL

Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901

(2012) Michael P Manns et al.   Expert Opinion On Drug Safety

Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis

(2012) Roeland Zoutendijk et al.   GUT

Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B

(2012) Jens M. Kittner et al.   JOURNAL OF CLINICAL VIROLOGY

523 ADD-ON PEG-IFN IMPROVES HBSAG KINETICS IN PATIENTS LONG-TERM FULLY SUPPRESSED BY NUCLEOS(T)IDE ANALOGS

(2012) P. Lampertico et al.   JOURNAL OF HEPATOLOGY

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients

(2012) Atsushi Ono et al.   JOURNAL OF HEPATOLOGY

Hepatitis B Surface Antigen Declines and Clearance During Long-Term Tenofovir Therapy in Patients Coinfected With HBV and HIV

(2012) R. Zoutendijk et al.   JOURNAL OF INFECTIOUS DISEASES

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

(2012) Patrick Marcellin et al.   LANCET

Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance and Clinical Safety

(2011) Man-Fung Yuen et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Tenofovir-Associated Kidney Toxicity in HIV-Infected Patients: A Review of the Evidence

(2011) Andrew M. Hall et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Antiviral drugs for HBV liver disease

(2011) Mauro Viganò et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response

(2011) Roeland Zoutendijk et al.   HEPATOLOGY

Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study

(2011) Yun-Fan Liaw et al.   HEPATOLOGY

740 HBSAG KINETICS IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR UP TO 4 YEARS

(2011) P. Marcellin et al.   JOURNAL OF HEPATOLOGY

Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients With Chronic Hepatitis B

(2010) Eugene R. Schiff et al.   Clinical Gastroenterology and Hepatology

Side effects of long-term oral antiviral therapy for hepatitis B

(2010) Robert J. Fontana   HEPATOLOGY

Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease

(2010) Yun-Fan Liaw et al.   HEPATOLOGY

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B

(2010) Ting-Tsung Chang et al.   HEPATOLOGY

Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir

(2010) Jurriën G.P. Reijnders et al.   JOURNAL OF HEPATOLOGY

Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function

(2009) Christian M. Lange et al.   HEPATOLOGY

Chronic hepatitis B: Update 2009

(2009) Anna S. F. Lok et al.   HEPATOLOGY

Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis

(2009) Ju Hyun Shim et al.   JOURNAL OF HEPATOLOGY

Hepatitis B virus infection

(2009) Yun-Fan Liaw et al.   LANCET

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

(2008) Yun-Fan Liaw et al.   Hepatology International